Alkermes expands Phase 1 trial of ALKS 4230 in combination with KEYTRUDA for advanced solid tumors
Irish biopharmaceutical company Alkermes has announced an expansion of its ongoing Phase 1 trial to evaluate the safety and anti-tumor activity of its immuno-oncology drug ... Read More
Vyriad and Merck launch Phase 1 trial for innovative immuno-oncology drug combination
Vyriad, a US-based biotech company, has partnered with Germany's Merck to initiate a Phase 1 clinical trial targeting metastatic colorectal cancer. This trial explores the ... Read More
India’s CDSCO grants APAC Biotech license for immuno-oncology drug Apceden
The Central Drugs Standard Control Organization (CDSCO), India's regulatory authority, has granted a commercial license to APAC Biotech for the marketing of Apceden, a Dendritic ... Read More